SCHEMBL7143529

SCHEMBL7143529

CC(C)NC(=O)CC[C@@H]1C[C@@H](S)CN1S(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ECE1 P42892 9/20 0.49
MME P08473 2/20 0.49
ACE P12821 2/20 0.49
PABPC1 P11940 1/20 0.46
APOBEC3A P31941 1/20 0.46
EIF4H Q15056 1/20 0.46
APOBEC3G Q9HC16 1/20 0.46
CCR4 P51679 1/20 0.44
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
HDAC9 Q9UKV0 1/20 0.43
HDAC5 Q9UQL6 1/20 0.43
EIF2AK3 Q9NZJ5 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7145551 1.00 ECE1 (0.49) ECE1MMEACEPABPC1APOBEC3A
SCHEMBL7136953 0.85 ECE1 (0.48) ECE1MMEACEHDAC3HDAC4
SCHEMBL7147193 0.85 ECE1 (0.48) ECE1MMEACEHDAC3HDAC4
SCHEMBL7138527 0.84 ECE1 (0.47) ECE1MMEACECCR4HDAC3
SCHEMBL7145542 0.84 ECE1 (0.47) ECE1MMEACECCR4HDAC3
SCHEMBL7142759 0.82 ALDH1A1 (0.47) ECE1MMEACECCR4HDAC3
SCHEMBL7137948 0.82 ALDH1A1 (0.47) ECE1MMEACECCR4HDAC3
SCHEMBL5404151 0.82 ECE1 (0.50) ECE1MMEACEAKR1C3PKM
SCHEMBL5409884 0.82 ECE1 (0.50) ECE1MMEACEAKR1C3PKM
SCHEMBL7143073 0.81 ECE1 (0.44) ECE1MMEACEHDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1303485-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2003-04-23 EP disclosed
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed
WO-2002006222-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP ECE1 4/4885MME 99/4885ACE 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.